Geoffrey M. Parker has bought stock on 18 days since Jan 2016
Chief Financial Officer at Allogene Therapeutics, Inc., and 4 other companies
SEC CIK 0001491874 · Filings on SEC.gov ↗
Geoffrey M. Parker's record
3 months after each buy, from the first price a copier could get.
5 buys since 2016 with 3 months of prices.
Companies
Every filing
22 filings since Jan 2016, newest first
Allogene Therapeutics, Inc.
Chief Financial Officer
Perrigo Co Plc
Director
Perrigo Co Plc
Director
Perrigo Co Plc
Director
Perrigo Co Plc
Director
Better Therapeutics, Inc.
Director
Perrigo Co Plc
Director
Better Therapeutics, Inc.
Director
Perrigo Co Plc
Director
Chemocentryx, Inc.
Director
Tricida, Inc.
CFO and EVP
Tricida, Inc.
Chief Fin. Officer, EVP
Chemocentryx, Inc.
Director
Tricida, Inc.
Chief Fin. Officer, EVP
Tricida, Inc.
Chief Fin. Officer, SVP
Chemocentryx, Inc.
Director
Perrigo Co Plc
Director
Tricida, Inc.
Chief Fin. Officer, SVP
Tricida, Inc.
Chief Fin. Officer, SVP
Perrigo Co Plc
Director
Chemocentryx, Inc.
Director
Chemocentryx, Inc.
Director
About Geoffrey M. Parker
Geoffrey M. Parker is a corporate insider and independent director at Perrigo Company plc, where he has served on the board since 2016 and sits on the Audit Committee.( He has extensive experience across the healthcare sector, with a career spanning senior leadership roles in biotechnology, pharmaceuticals, and healthcare investment banking.( Parker currently serves as Executive Vice President and Chief Financial Officer at Allogene Therapeutics, Inc., overseeing financial operations and business strategy as part of the company’s leadership team.(
Previously, Parker held key executive positions including Chief Operating Officer, Chief Financial Officer and Executive Vice President at Tricida, Inc., Chief Financial Officer at Anacor Pharmaceuticals, and Managing Director and Partner for Healthcare Investment Banking at Goldman Sachs, where he led the West Coast Healthcare Investment Banking group.( He has also served on the boards of companies such as Genomic Health, Sunesis Pharmaceuticals, Better Therapeutics, ChemoCentryx, and Sunessis Pharmaceuticals.( Parker earned a B.A. in Economics and Engineering Sciences from Dartmouth College and an MBA from the Stanford Graduate School of Business, providing a strong academic foundation for his nearly four decades of leadership in finance and life sciences.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.